Anticancer Prodrug Capable of Mitochondria-Targeting, Light-Triggered Release, and Fluorescence Monitoring.
Yun Lim JungYun Jae YangAnushree ShilSourav SarkarKyo Han AhnPublished in: ACS applied bio materials (2024)
Mitigating the adverse effects of anticancer agents requires innovative prodrug engineering. In this study, we showcase the potential of our o -quinone methide-based trigger-release-conjugation platform as a versatile tool for constructing advanced prodrug systems. Using this platform, we achieved the light-triggered release of an anticancer drug mechlorethamine, targeting mitochondrial DNA. The entire process was adeptly tracked through the emission of fluorescence signals, revealing notable effects across various cancer cell lines compared to a normal cell line. Exploring alternative cancer-associated triggers, including enzymes, and incorporating cancer/tumor-specific targeting elements could lead to effective prodrugs with reduced cytotoxicity.
Keyphrases
- cancer therapy
- mitochondrial dna
- papillary thyroid
- drug delivery
- copy number
- squamous cell
- high throughput
- single molecule
- drug release
- cell death
- emergency department
- energy transfer
- squamous cell carcinoma
- gene expression
- climate change
- dna methylation
- reactive oxygen species
- endoplasmic reticulum
- electronic health record
- drug induced